Driehaus Micro Cap Growth holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Driehaus Micro Cap Growth Fund DMCRX
- NAV / 1-Day Return $17.26 / −1.99 %
- Fund Size $499.2M
- Adjusted Expense Ratio 1.340%
- Net Expense Ratio 1.300%
- Fee Level: Distribution High
- Share Class Type No Load
- Morningstar Category Small Growth
- Equity Style Box (Funds) Small Growth
- Minimum Initial Investment $10,000
- Investment Status Limited
- TTM Yield 0.22%
- Turnover Ratio 142%
Morningstar’s Analysis DMCRX
Will DMCRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 17.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Praxis Precision Medicines Inc Ordinary Shares | 2.28 | 12M | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 2.27 | 12M | Healthcare |
Spyre Therapeutics Inc | 2.04 | 11M | Healthcare |
Bandwidth Inc Class A | 1.89 | 10M | Technology |
Amylyx Pharmaceuticals Inc | 1.75 | 9M | Healthcare |
Kiniksa Pharmaceuticals International PLC Class A | 1.65 | 9M | Healthcare |
Xometry Inc Ordinary Shares - Class A | 1.58 | 9M | Industrials |
Immunome Inc Ordinary Shares | 1.55 | 8M | Healthcare |
Adaptive Biotechnologies Corp | 1.47 | 8M | Healthcare |
Edgewise Therapeutics Inc | 1.44 | 8M | Healthcare |